期刊文献+

Expression of P450 and nuclear receptors in normal and end-stage Chinese livers 被引量:5

Expression of P450 and nuclear receptors in normal and end-stage Chinese livers
下载PDF
导出
摘要 AIM: To investigate the expression of P450 enzyme genes by using end-stage liver disease samples and trimmed normal Chinese donor livers. AIM:To investigate the expression of P450 enzyme genes by using end-stage liver disease samples and trimmed normal Chinese donor livers.METHODS:The end-stage liver disease samples[n=93,including hepatocellular carcinoma(HCC),peri-HCC tissue,hepatitis B virus cirrhosis,alcoholic cirrhosis,and severe cirrhosis]and trimmed normal Chinese donor livers(n=35)from The Institute of Organ Transplantation in Beijing,China.Total RNA was extracted,purified,and subjected to real-time RT-PCR analysis.RESULTS:For cytochrome P450 enzymes 1(CYP1)family,the expression of CYP1A2 was decreased 90%in HCC,80%in alcoholic cirrhosis,and 65%in severe cirrhosis.For CYP2 family,the expression of CAR was decreased 50%in HCC,but increased 50%in peri-HCC tissues.Similar decreases(about 50%)of CYP2B6,CYP2C9,CYP2C19,CYP2D6 and CYP2E1 were observed in HCC,as compared to peri-HCC tissues and normal livers.CYP2C19 were decreased in all end-stage liver diseases and CYP2E1 also decreased in alcoholic cirrhosis and severe cirrhosis.For CYP3 family,the expression of PXR was decreased 60%in HCC,together with decreases in CYP3A4,CYP3A5,and CYP3A7.In contrast,the expression of CYP3A7 was slightly increased in HBV cirrhosis.The expression of CYP4A11 was decreased85%in HCC,7%in alcoholic cirrhosis and severe liver cirrhosis,along with decreases in PPARα.The 93 endstage livers had much higher inter-individual variations in gene expression than 35 normal livers.CONCLUSION:The expression of CYP enzyme genes and corresponding nuclear receptors was generally decreased in end-stage liver diseases,and significant differences in gene expression were evident between peri-HCC and HCC.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第26期8681-8690,共10页 世界胃肠病学杂志(英文版)
基金 Supported by Grants from the Chinese 863 project,No.2012AA022409 Guizhou Science and Technology Foundation,No.2009-70019
关键词 Cytochrome P450 Nuclear receptors mRNA expression End-stage livers Chinese donor livers Hepatocellular carcinoma Cytochrome P450 Nuclear receptors mRNA expression
  • 相关文献

参考文献11

  • 1Bing-Ying Xu,Li-Ping Guo,Shui-Shan Lee,Qing-Ming Dong,Yi Tan,Hong Yao,Li-Hua Li,Che-Kit Lin,Hsiang-Fu Kung,Ming-Liang He.Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations[J].World Journal of Gastroenterology,2007,13(14):2100-2103. 被引量:6
  • 2Albader Albarmawi,David Czock,Annika Gauss,Robert Ehehalt,Justo Lorenzo Bermejo,Jürgen Burhenne,Tom M. Ganten,Peter Sauer,Walter E. Haefeli.CYP3A activity in severe liver cirrhosis correlates with C hild– P ugh and model for end‐stage liver disease ( MELD ) scores[J].Br J Clin Pharmacol.2014(1)
  • 3Ioannis Koutsounas,Stamatios Theocharis,Efstratios Patsouris,Constantinos Giaginis.Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease[J].Current Drug Metabolism.2013(3)
  • 4Dirk Theile,Walter Emil Haefeli,Helmut Karl Seitz,Gunda Millonig,Johanna Weiss,Sebastian Mueller.Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease[J].Alcohol Clin Exp Res.2012
  • 5Iain A.M. MacPhee.Pharmacogenetic biomarkers: cytochrome P450 3A5[J].Clinica Chimica Acta (-).2011(17-18)
  • 6J. Aubert,K. Begriche,L. Knockaert,M.A. Robin,B. Fromenty.Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role[J].Clinics and Research in Hepatology and Gastroenterology.2011(10)
  • 7Andreas Schmidt,Albert Braeuning,Peter Ruck,Guido Seitz,Sorin Armeanu-Ebinger,Joerg Fuchs,Steven W. Warmann,Michael Schwarz.Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma[J].Toxicology.2011(1)
  • 8Christa Buechler,Thomas S. Weiss.Does Hepatic Steatosis Affect Drug Metabolizing Enzymes in the Liver?[J].Current Drug Metabolism.2011(1)
  • 9Susanne Haas,Sabine Merkelbach-Bruse,Christina Justenhoven,Hiltrud Brauch,Hans-Peter Fischer.Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver[J].Pathology - Research and Practice.2009(10)
  • 10Patricia Neafsey,Gary Ginsberg,Dale Hattis,Babasaheb Sonawane.Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity[J].Journal of Toxicology and Environmental Health Part B (-).2009(5-6)

二级参考文献16

  • 1[1]Pascussi JM,Gerbal-Chaloin S,Drocourt L,Maurel P,Vilarem MJ.The expression of CYP2B6,CYP2C9 and CYP3A4 genes:a tangle of networks of nuclear and steroid receptors.Biochim Biophys Acta 2003; 1619:243-253
  • 2[2]Lang T,Klein K,Fischer J,Nussler AK,Neuhaus P,Hofmann U,Eichelbaum M,Schwab M,Zanger UM.Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.Pharmacogenetics 2001;11:399-415
  • 3[3]Haas DW,Ribaudo HJ,Kim RB,Tierney C,Wilkinson GR,Gulick RM,Clifford DB,Hulgan T,Marzolini C,Acosta EP.Pharmacogenetics of efavirenz and central nervous system side effects:an Adult AIDS Clinical Trials Group study.AIDS 2004; 18:2391-2400
  • 4[4]Tsuchiya K,Gatanaga H,Tachikawa N,Teruya K,Kikuchi Y,Yoshino M,Kuwahara T,Shirasaka T,Kimura S,Oka S.Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.Biochem Biophys Res Commun 2004; 319:1322-1326
  • 5[5]Zukunft J,Lang T,Richter T,Hirsch-Ernst KI,Nussler AK,Klein K,Schwab M,Eichelbaum M,Zanger UM.A naturalCYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.Mol Pharmacol 2005; 67:1772-1782
  • 6[6]Kirchheiner J,Klein C,Meineke I,Sasse J,Zanger UM,Murdter TE,Roots I,Brockmoller J.Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.Pharmacogenetics 2003; 13:619-626
  • 7[7]Lamba V,Lamba J,Yasuda K,Strom S,Davila J,Hancock ML,Fackenthal JD,Rogan PK,Ring B,Wrighton SA,Schuetz EG.Hepatic CYP2B6 expression:gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.J Pharmacol Exp Ther 2003;307:906-922
  • 8[8]Crettol S,Deglon JJ,Besson J,Croquette-Krokkar M,Gothuey I,Hammig R,Monnat M,Huttemann H,Baumann P,Eap CB.Methadone enantiomer plasma levels,CYP2B6,CYP2C19,and CYP2C9 genotypes,and response to treatment.Clin Pharmacol Ther 2005; 78:593-604
  • 9[9]Haas DW,Smeaton LM,Shafer RW,Robbins GK,Morse GD,Labbe L,Wilkinson GR,Clifford DB,D'Aquila RT,De Gruttola V,Pollard RB,Merigan TC,Hirsch MS,George AL Jr,Donahue JP,Kim RB.Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir:an Adult Aids Clinical Trials Group Study.J Infect Dis 2005; 192:1931-1942
  • 10[10]Jacob RM,Johnstone EC,Neville MJ,Walton RT.Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping.Clin Chem 2004; 50:1372-1377

共引文献7

同被引文献10

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部